All
Cosela May Decrease Chemo-Related Blood Complications During Lung Cancer Treatment
July 18th 2022Cosela tended to decrease myelosuppressive events — when the bone marrow is not working sufficiently to produce blood cells and platelets — in patients receiving chemotherapy for extensive-stage small cell lung cancer.
Oncologist Who Specializes in Treating Rare Blood Cancers ‘Learns from Patients Every Day’
July 15th 2022An expert from the Tisch Cancer Institute discusses how he learns from patients and their caregivers, and how their insight has helped lead advancements in the treatment of myeloproliferative neoplasms, a group of rare blood cancers.
FDA Fast Tracks Investigational Drug for the Treatment of Recurrent Brain Cancer
July 15th 2022The safety, optimal dosage and efficacy of the investigational drug is currently being evaluated in a first-in-human trial in patients with recurrent high-grade glioblastoma, a type of spinal cord and brain cancer.
FDA Lifts Hold on Trial Investigating Novel Drug in Patients With High-Risk Breast Cancer
July 14th 2022The FDA has permitted the manufacturer of a novel drug to continue a phase 3 clinical trial investigating the effects of treatment with a novel drug in patients with HER2/neu-positive primary breast cancer.
Amazon and Fred Hutch Partner to Investigate Safety, Efficacy of Cancer Vaccine
July 14th 2022Amazon and Fred Hutchinson Cancer Center recently launched an early-phase clinical trial to assess the safety and efficacy of a cancer vaccine in the treatment of patients with late-stage skin cancer or hormone receptor-positive, HER2-negative breast cancer.
Early-Phase Trial Assessing Novel CAR-T Cell Therapy in a Type of Blood Cancer Terminated
July 12th 2022The manufacturer of the novel CAR-T cell therapy announced it terminated an early-phase trial investigating the treatment’s efficacy after there was a lack of benefit in patients with relapsed or refractory T-cell lymphoma, a type of blood cancer.
Study of Novel Drug Combo in Head and Neck Cancer Closed After Several Patient Deaths
July 12th 2022A clinical trial reviewing the safety and efficacy of a treatment regimen of enoblituzumab in combination with either retifanlimab or tebotelimab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck has been stopped by the manufacturer of the cancer drugs.